QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03552718
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02751528
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Sanford Cancer Center, Sioux Falls, South Dakota, United States
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- NantBioScience, Inc.
- Registration Number
- NCT02582827
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01318642
- Locations
- 🇬🇧
Guys Hospital, London, United Kingdom
🇬🇧Research Site, Preston, United Kingdom
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT00891930
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT00788957
© Copyright 2024. All Rights Reserved by MedPath